Morning Overview on MSN
New Apogee Therapeutics data reveal long-acting eczema drug cuts flares with fewer shots
Apogee Therapeutics is advancing APG777, an experimental antibody designed to treat moderate-to-severe atopic dermatitis with far fewer injections than existing biologics. Early clinical data show the ...
Living with eczema means dealing with constant skin irritation, relentless itching and the frustration of managing an overactive immune system that treats harmless substances like mortal enemies. But ...
Eczema is way more common than you think. Per Healthline, 1 in 10 people will develop eczema in their lifetime. Eczema is seen so differently on so many bodies and people, but the most common symptoms ...
StudyFinds on MSN
The physics of eczema: A math model predicts the minimum dose to control severe flares
In A Nutshell Researchers used computer modeling and physics-based math to calculate the minimum antibiotic and moisturizer doses needed to push severe eczema into remission and keep it there. The ...
'Flare' is commonly used in eczema care and clinical research, but with little agreement on what it means. NOVATO, Calif., Sept. 13, 2024 /PRNewswire/ -- The National Eczema Association (NEA) today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results